Search

everythinglearnresearchcommunity

for

Search:↓

This study explored the use of the Janus kinase (JAK) inhibitor tofacitinib in treating patients with both alopecia areata (AA) and inflammatory bowel disease (IBD), specifically ulcerative colitis (UC) and Crohn disease. A retrospective chart review was conducted on 9 patients aged 18 and older, revealing that 6 out of 7 patients with active IBD achieved remission of both IBD and AA with tofacitinib. The study highlighted the potential overlap in the pathobiology of AA and IBD and suggested that JAK inhibitors could be a viable treatment option for patients with these comorbid autoimmune conditions. However, the study was limited by its small sample size and the fact that all patients were from a single clinic.

A 23-year-old female with alopecia totalis and lichen planus hypertrophicus showed significant improvement after treatment with oral tofacitinib, a JAK 1/3 inhibitor. Initially treated with cyclosporine without success, the patient began tofacitinib at 5 mg twice daily, leading to hair regrowth and improvement of skin lesions within 2-2.5 months, with notable progress at 9 months. Tofacitinib was well tolerated, with no serious adverse effects, and was followed by methotrexate for maintenance. This case suggests tofacitinib as a promising treatment for severe, treatment-resistant cases of alopecia areata and lichen planus hypertrophicus.

The document summarizes multiple studies presented at the 2024 WDS Forum. A retrospective cohort study involving 37,078 female alopecia patients found no increased risk of gynecological tumors with 5-alpha reductase inhibitors or spironolactone compared to minoxidil. Another study indicated an increased risk of new-onset alopecia with glucagon-like-peptide-1 receptor agonists. Research highlighted a correlation between sanitary pad use and dermatitis, and emphasized early intervention for hidradenitis suppurativa in Hispanic patients. A pilot study in Massachusetts showed community-based education improved skin cancer prevention awareness. Additional studies found metformin associated with higher survival rates in certain skin cancers, increased acne risk with LNG-IUDs, high accuracy of machine learning in basal cell carcinoma detection, and a higher risk of spontaneous abortion with JAK-inhibitors during pregnancy. Lastly, inclusivity in skincare advertising was found to influence individuals with darker skin tones, and a study on CCCA in Black women suggested potential autoimmune involvement.